Abstract
Approximately one-third of severe asthma patients are eligible for both anti-IgE and anti-IL-5/5R therapy. However, it is not clear whether one class of biologic works better than the other amongst patients eligible for both.
Original language | English |
---|---|
Article number | A1614 |
Number of pages | 1 |
Journal | American Journal of Respiratory and Critical Care Medicine |
Volume | 203 |
Early online date | 19 May 2021 |
DOIs | |
Publication status | Published - 2021 |
Event | ATS International Conference Committee: ATS 2021 - Virtual event Duration: 14 May 2021 → 19 May 2021 https://conference.thoracic.org/ |